News stories about Regulus Therapeutics (NASDAQ:RGLS) have trended somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Regulus Therapeutics earned a news sentiment score of 0.09 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 46.719055737187 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Regulus Therapeutics Inc. (NASDAQ:RGLS) Given Consensus Recommendation of “Hold” by Brokerages (americanbankingnews.com)
- Regulus Therapeutics Inc. (RGLS) Earns “Ourperform” Rating from Wedbush (americanbankingnews.com)
- Regulus Therapeutics Inc (RGLS) Showing Negative Momentum in the Technicals – Evergreen Caller (evergreencaller.com)
- Regulus Therapeutics’ (RGLS) Hold Rating Reaffirmed at Needham & Company LLC (americanbankingnews.com)
- Regulus Therapeutics Inc. (RGLS) Releases Quarterly Earnings Results, Misses Estimates By $0.10 EPS (americanbankingnews.com)
Shares of Regulus Therapeutics (RGLS) traded down 3.7134% during midday trading on Tuesday, reaching $0.9516. The company’s stock had a trading volume of 515,197 shares. Regulus Therapeutics has a 52 week low of $0.86 and a 52 week high of $3.81. The firm’s 50 day moving average is $1.00 and its 200 day moving average is $1.34. The firm’s market capitalization is $50.61 million.
Regulus Therapeutics (NASDAQ:RGLS) last announced its earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.31) by $0.10. Regulus Therapeutics had a negative return on equity of 173.20% and a negative net margin of 31,460.47%. The business had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.02 million. Equities analysts forecast that Regulus Therapeutics will post ($1.10) EPS for the current fiscal year.
Several research firms recently issued reports on RGLS. Wedbush reiterated an “ourperform” rating and issued a $6.00 price objective on shares of Regulus Therapeutics in a report on Tuesday, June 13th. ValuEngine downgraded Regulus Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Chardan Capital cut their price target on Regulus Therapeutics from $5.00 to $2.50 and set a “buy” rating on the stock in a report on Tuesday, June 13th. Zacks Investment Research upgraded Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.00 price target on the stock in a report on Wednesday, July 12th. Finally, BMO Capital Markets restated a “hold” rating on shares of Regulus Therapeutics in a report on Monday, May 15th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and one has given a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $3.58.
TRADEMARK VIOLATION WARNING: This report was first posted by BBNS and is the property of of BBNS. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://baseballnewssource.com/markets/regulus-therapeutics-nasdaqrgls-receiving-somewhat-positive-news-coverage-analysis-finds/1410167.html.
In other Regulus Therapeutics news, CFO Daniel R. Chevallard bought 54,945 shares of the company’s stock in a transaction dated Tuesday, July 25th. The shares were acquired at an average cost of $0.91 per share, with a total value of $49,999.95. Following the completion of the transaction, the chief financial officer now owns 59,415 shares in the company, valued at $54,067.65. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director William H. Rastetter bought 274,725 shares of the company’s stock in a transaction dated Tuesday, July 25th. The shares were acquired at an average cost of $0.91 per share, for a total transaction of $249,999.75. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 549,450 shares of company stock worth $500,000. Corporate insiders own 4.80% of the company’s stock.
Regulus Therapeutics Company Profile
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.
Receive News & Ratings for Regulus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc. and related companies with our FREE daily email newsletter.